Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: Experience from the placebo-controlled diabetic retinopathy candesartan trials
Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists
Quan A (2006) Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Human Development 82:23-28
Major congenital malformations after first-trimester exposure to ACE inhibitors
DOI 10.1056/NEJMoa055202
Cooper WO, Hernandez-Diaz S, Arbogast PG et al (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354:2443-2451 (Pubitemid 43855047)
Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants
Lennestål R, Otterblad Olausson P, Källén B (2009) Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 65:615-625
Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations
Caton AR, Bell EM, Druschel CM et al (2009) Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 54:63-70
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomised, placebocontrolled trials
Chaturvedi N, Porta M, Klein R et al (2008) Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebocontrolled trials. Lancet 372:394-402
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomised placebo-controlled trial
Sjølie AK, Klein R, Porta M et al (2008) Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372:1385-1393
Early expression of all the components of the renin-angiotensin-system in human development
Schultz S, Moullec J-M, Corvol P, Gasic J-M (1996) Early expression of all the components of the renin-angiotensin system in human development. Am J Pathology 149:2067-2079 (Pubitemid 26415223)